Jazz Pharmaceuticals PLC
JAZZHealthcare|Biotechnology|Ireland
$243.79
-3.09 (-1.25%)
DCF (FCF)
$213.42
Earnings Power
$74.91
About
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Stock Price
+116.7%(1Y)
Pipeline Summary
288 total trials64
Phase 1
119
Phase 2
82
Phase 3
15
Phase 4
Completed: 159Recruiting: 36Terminated: 37Unknown: 5NO_LONGER_AVAILABLE: 5Active: 14Withdrawn: 19NOT_YET_RECRUITING: 8APPROVED_FOR_MARKETING: 5
Active Trials (50)
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
NCT05636111Ovarian Cancer
Phase 1Recruiting
Enrollment: 34 participants
ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids
NCT05629702Glioblastoma
Phase 2Recruiting
Enrollment: 120 participants
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
NCT05091567Small-Cell Lung Cancer
Phase 3Active
Enrollment: 660 participants
CPX-351 Plus Enasidenib for Relapsed AML
NCT03825796Recurrent Acute Myeloid Leukemia
Phase 2Active
Enrollment: 2 participants
Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy
NCT06113237Maternal Complications
Recruiting
Enrollment: 50 participants
BioScore
5.6/10
Watchlist
Ownership
Recent Insider Trades
COZADD BRUCE CSELL
2026-07-016,000 shares @ $240.47
Smith Mark DouglasSELL
2026-06-151,157 shares @ $230.55
Patil Neena MSELL
2026-06-101,200 shares @ $231.83
COZADD BRUCE CSELL
2026-06-016,000 shares @ $235.12
Patil Neena MSELL
2026-05-281,192 shares @ $236.97
Recent News
2026-07-09 19:39:35
2026-07-07 13:04:28
2026-06-17 22:02:46
2026-06-17 12:00:05
2026-06-16 21:00:05
Data last updated: Jul 12, 2026, 07:27 PM